Here's how LINK.SPRINGER.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

LINK . SPRINGER . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Link.springer.com Make Money
  6. Keywords
  7. Topics
  8. Schema
  9. External Links
  10. Analytics And Tracking
  11. Libraries
  12. CDN Services

We are analyzing https://link.springer.com/article/10.1007/s00262-011-1184-2.

Title:
Hypericin-based photodynamic therapy induces surface exposure of damage-associated molecular patterns like HSP70 and calreticulin | Cancer Immunology, Immunotherapy
Description:
Surface-exposed HSP70 and calreticulin are damage-associated molecular patterns (DAMPs) crucially involved in modulating the success of cancer therapy. Photodynamic therapy (PDT) involves the administration of a photosensitising (PTS) agent followed by visible light-irradiation. The reactive oxygen species that are thus generated directly kill tumours by damaging their microvasculature and inducing a local inflammatory reaction. PDT with the PTS photofrin is associated with DAMPs exposure, but the same is not true for other PTSs. Here, we show that when cancer cells are treated with hypericin-based PDT (Hyp-PDT), they surface-expose both HSP70 and calreticulin (CRT). Induction of CRT exposure was not accompanied by co-exposure of ERp57, but this did not compromise the ability of the exposed CRT to regulate the phagocytosis of Hyp-PDT-treated cancer cells by dendritic cells. Interestingly, we found that Hyp-PDT-induced CRT exposure (in contrast to anthracycline-induced CRT exposure) was independent of the presence of ERp57. Our results indicate that Hyp-PDT is a potential anti-cancer immunogenic modality.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {๐Ÿ“š}

  • Science
  • Education
  • Health & Fitness

Content Management System {๐Ÿ“}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {๐Ÿ“ˆ}

What is the average monthly size of link.springer.com audience?

๐ŸŒ  Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 7,642,828 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {๐Ÿ’ธ}

We can't see how the site brings in money.

Many websites are intended to earn money, but some serve to share ideas or build connections. Websites exist for all kinds of purposes. This might be one of them. Link.springer.com might have a hidden revenue stream, but it's not something we can detect.

Keywords {๐Ÿ”}

article, pubmed, google, scholar, cas, cancer, cell, photodynamic, therapy, research, death, cells, calreticulin, agostinis, molecular, krysko, vandenabeele, exposure, hsp, garg, damps, surface, damageassociated, patterns, author, immunol, privacy, cookies, peter, crt, erp, korbelik, content, publish, search, hypericinbased, dmitri, pdt, access, van, zitvogel, kroemer, immunity, tumor, belgium, fwovlaanderen, ghent, data, policy, information,

Topics {โœ’๏ธ}

complement-independent antibody-mediated phagocytosis pdt-mediated photo-oxidative stress month download article/chapter hypericin-mediated photodynamic therapy hyp-pdt-induced crt exposure photodynamic therapy-generated vaccines photodynamic therapy-generated vaccine hyp-pdt-treated cancer cells anthracycline-induced crt exposure hypericin-based pdt pre-apoptotic calreticulin exposure endoplasmic reticulum depletion tumor-specific immune response article cancer immunology hypericin-induced photosensitization heat shock proteins kryskoย &ย peter vandenabeele photodynamic therapy treatment full article pdf privacy choices/manage cookies calreticulin exposure dictates federal research program hsp70 translocation induced vesalius research center garg ad european economic area article garg scientific research flanders immunogenic cell death cancer cell death molecular biomedical research author information authors anti-tumour immunity surface expression visible light-irradiation reactive oxygen species local inflammatory reaction murphy-ullrich je multidomain proapoptotic bax ugent mrp initiative fp7 apo-sys 200767 shaping cell death tumor cell death conditions privacy policy group-id consortium biomedical molecular biology cancer immunol immunother photodynamic therapy hela cells leads ko mef cells

Schema {๐Ÿ—บ๏ธ}

WebPage:
      mainEntity:
         headline:Hypericin-based photodynamic therapy induces surface exposure of damage-associated molecular patterns like HSP70 and calreticulin
         description:Surface-exposed HSP70 and calreticulin are damage-associated molecular patterns (DAMPs) crucially involved in modulating the success of cancer therapy. Photodynamic therapy (PDT) involves the administration of a photosensitising (PTS) agent followed by visible light-irradiation. The reactive oxygen species that are thus generated directly kill tumours by damaging their microvasculature and inducing a local inflammatory reaction. PDT with the PTS photofrin is associated with DAMPs exposure, but the same is not true for other PTSs. Here, we show that when cancer cells are treated with hypericin-based PDT (Hyp-PDT), they surface-expose both HSP70 and calreticulin (CRT). Induction of CRT exposure was not accompanied by co-exposure of ERp57, but this did not compromise the ability of the exposed CRT to regulate the phagocytosis of Hyp-PDT-treated cancer cells by dendritic cells. Interestingly, we found that Hyp-PDT-induced CRT exposure (in contrast to anthracycline-induced CRT exposure) was independent of the presence of ERp57. Our results indicate that Hyp-PDT is a potential anti-cancer immunogenic modality.
         datePublished:2011-12-23T00:00:00Z
         dateModified:2011-12-23T00:00:00Z
         pageStart:215
         pageEnd:221
         sameAs:https://doi.org/10.1007/s00262-011-1184-2
         keywords:
            Calreticulin
            HSP70
            Photodynamic therapy
            Hypericin
            Cancer
            DAMPs
            Oncology
            Immunology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-011-1184-2/MediaObjects/262_2011_1184_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-011-1184-2/MediaObjects/262_2011_1184_Fig2_HTML.gif
         isPartOf:
            name:Cancer Immunology, Immunotherapy
            issn:
               1432-0851
               0340-7004
            volumeNumber:61
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Abhishek D. Garg
               affiliation:
                     name:Catholic University of Leuven
                     address:
                        name:Cell Death Research and Therapy Unit, Department of Molecular Cell Biology, Faculty of Medicine, Catholic University of Leuven, Leuven, Belgium
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Dmitri V. Krysko
               affiliation:
                     name:VIB
                     address:
                        name:Molecular Signaling and Cell Death Unit, Department for Molecular Biomedical Research, VIB, Ghent, Belgium
                        type:PostalAddress
                     type:Organization
                     name:Ghent University
                     address:
                        name:Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Peter Vandenabeele
               affiliation:
                     name:VIB
                     address:
                        name:Molecular Signaling and Cell Death Unit, Department for Molecular Biomedical Research, VIB, Ghent, Belgium
                        type:PostalAddress
                     type:Organization
                     name:Ghent University
                     address:
                        name:Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Patrizia Agostinis
               affiliation:
                     name:Catholic University of Leuven
                     address:
                        name:Cell Death Research and Therapy Unit, Department of Molecular Cell Biology, Faculty of Medicine, Catholic University of Leuven, Leuven, Belgium
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Hypericin-based photodynamic therapy induces surface exposure of damage-associated molecular patterns like HSP70 and calreticulin
      description:Surface-exposed HSP70 and calreticulin are damage-associated molecular patterns (DAMPs) crucially involved in modulating the success of cancer therapy. Photodynamic therapy (PDT) involves the administration of a photosensitising (PTS) agent followed by visible light-irradiation. The reactive oxygen species that are thus generated directly kill tumours by damaging their microvasculature and inducing a local inflammatory reaction. PDT with the PTS photofrin is associated with DAMPs exposure, but the same is not true for other PTSs. Here, we show that when cancer cells are treated with hypericin-based PDT (Hyp-PDT), they surface-expose both HSP70 and calreticulin (CRT). Induction of CRT exposure was not accompanied by co-exposure of ERp57, but this did not compromise the ability of the exposed CRT to regulate the phagocytosis of Hyp-PDT-treated cancer cells by dendritic cells. Interestingly, we found that Hyp-PDT-induced CRT exposure (in contrast to anthracycline-induced CRT exposure) was independent of the presence of ERp57. Our results indicate that Hyp-PDT is a potential anti-cancer immunogenic modality.
      datePublished:2011-12-23T00:00:00Z
      dateModified:2011-12-23T00:00:00Z
      pageStart:215
      pageEnd:221
      sameAs:https://doi.org/10.1007/s00262-011-1184-2
      keywords:
         Calreticulin
         HSP70
         Photodynamic therapy
         Hypericin
         Cancer
         DAMPs
         Oncology
         Immunology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-011-1184-2/MediaObjects/262_2011_1184_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-011-1184-2/MediaObjects/262_2011_1184_Fig2_HTML.gif
      isPartOf:
         name:Cancer Immunology, Immunotherapy
         issn:
            1432-0851
            0340-7004
         volumeNumber:61
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Abhishek D. Garg
            affiliation:
                  name:Catholic University of Leuven
                  address:
                     name:Cell Death Research and Therapy Unit, Department of Molecular Cell Biology, Faculty of Medicine, Catholic University of Leuven, Leuven, Belgium
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Dmitri V. Krysko
            affiliation:
                  name:VIB
                  address:
                     name:Molecular Signaling and Cell Death Unit, Department for Molecular Biomedical Research, VIB, Ghent, Belgium
                     type:PostalAddress
                  type:Organization
                  name:Ghent University
                  address:
                     name:Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Peter Vandenabeele
            affiliation:
                  name:VIB
                  address:
                     name:Molecular Signaling and Cell Death Unit, Department for Molecular Biomedical Research, VIB, Ghent, Belgium
                     type:PostalAddress
                  type:Organization
                  name:Ghent University
                  address:
                     name:Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Patrizia Agostinis
            affiliation:
                  name:Catholic University of Leuven
                  address:
                     name:Cell Death Research and Therapy Unit, Department of Molecular Cell Biology, Faculty of Medicine, Catholic University of Leuven, Leuven, Belgium
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer Immunology, Immunotherapy
      issn:
         1432-0851
         0340-7004
      volumeNumber:61
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Catholic University of Leuven
      address:
         name:Cell Death Research and Therapy Unit, Department of Molecular Cell Biology, Faculty of Medicine, Catholic University of Leuven, Leuven, Belgium
         type:PostalAddress
      name:VIB
      address:
         name:Molecular Signaling and Cell Death Unit, Department for Molecular Biomedical Research, VIB, Ghent, Belgium
         type:PostalAddress
      name:Ghent University
      address:
         name:Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium
         type:PostalAddress
      name:VIB
      address:
         name:Molecular Signaling and Cell Death Unit, Department for Molecular Biomedical Research, VIB, Ghent, Belgium
         type:PostalAddress
      name:Ghent University
      address:
         name:Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium
         type:PostalAddress
      name:Catholic University of Leuven
      address:
         name:Cell Death Research and Therapy Unit, Department of Molecular Cell Biology, Faculty of Medicine, Catholic University of Leuven, Leuven, Belgium
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Abhishek D. Garg
      affiliation:
            name:Catholic University of Leuven
            address:
               name:Cell Death Research and Therapy Unit, Department of Molecular Cell Biology, Faculty of Medicine, Catholic University of Leuven, Leuven, Belgium
               type:PostalAddress
            type:Organization
      name:Dmitri V. Krysko
      affiliation:
            name:VIB
            address:
               name:Molecular Signaling and Cell Death Unit, Department for Molecular Biomedical Research, VIB, Ghent, Belgium
               type:PostalAddress
            type:Organization
            name:Ghent University
            address:
               name:Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium
               type:PostalAddress
            type:Organization
      name:Peter Vandenabeele
      affiliation:
            name:VIB
            address:
               name:Molecular Signaling and Cell Death Unit, Department for Molecular Biomedical Research, VIB, Ghent, Belgium
               type:PostalAddress
            type:Organization
            name:Ghent University
            address:
               name:Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium
               type:PostalAddress
            type:Organization
      name:Patrizia Agostinis
      affiliation:
            name:Catholic University of Leuven
            address:
               name:Cell Death Research and Therapy Unit, Department of Molecular Cell Biology, Faculty of Medicine, Catholic University of Leuven, Leuven, Belgium
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Cell Death Research and Therapy Unit, Department of Molecular Cell Biology, Faculty of Medicine, Catholic University of Leuven, Leuven, Belgium
      name:Molecular Signaling and Cell Death Unit, Department for Molecular Biomedical Research, VIB, Ghent, Belgium
      name:Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium
      name:Molecular Signaling and Cell Death Unit, Department for Molecular Biomedical Research, VIB, Ghent, Belgium
      name:Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium
      name:Cell Death Research and Therapy Unit, Department of Molecular Cell Biology, Faculty of Medicine, Catholic University of Leuven, Leuven, Belgium
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {๐Ÿ”—}(119)

Analytics and Tracking {๐Ÿ“Š}

  • Google Tag Manager

Libraries {๐Ÿ“š}

  • Clipboard.js
  • Prism.js

CDN Services {๐Ÿ“ฆ}

  • Crossref

4.02s.